125 related articles for article (PubMed ID: 24095110)
1. Telomere length, c-myc and mad-1 expression could represent prognosis markers of myelodysplastic syndrome.
Poloni A; Serrani F; Berardinelli E; Maurizi G; Mariani M; Costantini B; Trappolini S; Mancini S; Olivieri A; Leoni P
Leuk Res; 2013 Nov; 37(11):1538-44. PubMed ID: 24095110
[TBL] [Abstract][Full Text] [Related]
2. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes.
Ohyashiki JH; Iwama H; Yahata N; Ando K; Hayashi S; Shay JW; Ohyashiki K
Clin Cancer Res; 1999 May; 5(5):1155-60. PubMed ID: 10353751
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?
Sieglová Z; Zilovcová S; Cermák J; Ríhová H; Brezinová D; Dvoráková R; Marková M; Maaloufová J; Sajdová J; Brezinová J; Zemanová Z; Michalová K
Leuk Res; 2004 Oct; 28(10):1013-21. PubMed ID: 15289012
[TBL] [Abstract][Full Text] [Related]
4. Telomerase activity in myelodysplastic syndromes.
Gürkan E; Tanriverdi K; Başlamişli F
Leuk Res; 2005 Oct; 29(10):1131-9. PubMed ID: 16111531
[TBL] [Abstract][Full Text] [Related]
5. Telomerase, hTERT and splice variants in patients with myelodysplastic syndromes.
Dong W; Qian Y; Yang L
Leuk Res; 2014 Jul; 38(7):830-5. PubMed ID: 24844605
[TBL] [Abstract][Full Text] [Related]
6. Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups.
Gadji M; Adebayo Awe J; Rodrigues P; Kumar R; Houston DS; Klewes L; Dièye TN; Rego EM; Passetto RF; de Oliveira FM; Mai S
Clin Cancer Res; 2012 Jun; 18(12):3293-304. PubMed ID: 22539801
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of Telomere Lengths and Telomerase Activity in Myelodysplastic Syndrome.
Park HS; Choi J; See CJ; Kim JA; Park SN; Im K; Kim SM; Lee DS; Hwang SM
Ann Lab Med; 2017 May; 37(3):195-203. PubMed ID: 28224765
[TBL] [Abstract][Full Text] [Related]
9. Elevated telomerase activity, c-MYC-, and hTERT mRNA expression: association with tumour progression in malignant lipomatous tumours.
Schneider-Stock R; Boltze C; Jäger V; Epplen J; Landt O; Peters B; Rys J; Roessner A
J Pathol; 2003 Apr; 199(4):517-25. PubMed ID: 12635143
[TBL] [Abstract][Full Text] [Related]
10. [Expression of cell cycle control genes in myelodysplastic syndromes].
Shi J; Shao ZH; Liu H; Jia HR; Sun J; Bai J; Cao YR; Wang XL; Tu MF
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):10-4. PubMed ID: 15946501
[TBL] [Abstract][Full Text] [Related]
11. Increase of telomerase activity and hTERT expression in myelodysplastic syndromes.
Briatore F; Barrera G; Pizzimenti S; Toaldo C; Casa CD; Laurora S; Pettazzoni P; Dianzani MU; Ferrero D
Cancer Biol Ther; 2009 May; 8(10):883-9. PubMed ID: 19270495
[TBL] [Abstract][Full Text] [Related]
12. Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes.
Gianelli U; Fracchiolla NS; Cortelezzi A; Pellegrini C; Savi F; Moro A; Grimoldi MG; Deliliers GL; Coggi G; Bosari S
Ann Hematol; 2007 Mar; 86(3):185-9. PubMed ID: 17124585
[TBL] [Abstract][Full Text] [Related]
13. Ets2 binding site single nucleotide polymorphism at the hTERT gene promoter--effect on telomerase expression and telomere length maintenance in non-small cell lung cancer.
Hsu CP; Hsu NY; Lee LW; Ko JL
Eur J Cancer; 2006 Jul; 42(10):1466-74. PubMed ID: 16737810
[TBL] [Abstract][Full Text] [Related]
14. MDS shows a higher expression of hTERT and alternative splice variants in unactivated T-cells.
Dong W; Wu L; Sun H; Ren X; Epling-Burnette PK; Yang L
Oncotarget; 2016 Nov; 7(44):71904-71914. PubMed ID: 27655690
[TBL] [Abstract][Full Text] [Related]
15. Telomere length and telomerase subunits as diagnostic and prognostic biomarkers in Barrett carcinoma.
Gertler R; Doll D; Maak M; Feith M; Rosenberg R
Cancer; 2008 May; 112(10):2173-80. PubMed ID: 18348304
[TBL] [Abstract][Full Text] [Related]
16. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.
Cilloni D; Gottardi E; Messa F; Fava M; Scaravaglio P; Bertini M; Girotto M; Marinone C; Ferrero D; Gallamini A; Levis A; Saglio G;
J Clin Oncol; 2003 May; 21(10):1988-95. PubMed ID: 12743153
[TBL] [Abstract][Full Text] [Related]
17. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma.
Gertler R; Rosenberg R; Stricker D; Friederichs J; Hoos A; Werner M; Ulm K; Holzmann B; Nekarda H; Siewert JR
J Clin Oncol; 2004 May; 22(10):1807-14. PubMed ID: 15143073
[TBL] [Abstract][Full Text] [Related]
18. Distinct expression profiles of MSI2 and NUMB genes in myelodysplastic syndromes and acute myeloid leukemia patients.
Pereira JK; Traina F; Machado-Neto JA; Duarte Ada S; Lopes MR; Saad ST; Favaro P
Leuk Res; 2012 Oct; 36(10):1300-3. PubMed ID: 22784712
[TBL] [Abstract][Full Text] [Related]
19. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.
Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA
Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644
[TBL] [Abstract][Full Text] [Related]
20. Evi-1 and MDS1-Evi-1 genes in pathogenesis of myelodysplastic syndromes and post-MDS acute myeloid leukemia.
Xu K; Wang L; Hao Y; Shao Z; Meng Q; Li K; Chao H; Tang K; Wang L
Chin Med J (Engl); 1999 Dec; 112(12):1112-8. PubMed ID: 11721451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
